Accerelon plan phase 2 trial for people with FSH

Viewing 1 post (of 1 total)
  • #135123
    Accerelon plan phase 2 trial for people with FSH

    One way scientists are trying to improve muscle strength in people with neuromuscular conditions is by blocking the activity of proteins that negatively regulate muscle growth (such as myostatin).

    The pharmaceutical company Acceleron, have developed a drug called ACE-083, which inhibits myostatin and has recently been shown to increase muscle volume in healthy people on a phase 1 trial. The company are now planning to advance the drug into phase 2 clinical trial and test its effectiveness in people with facioscapulohumeral muscular dystrophy.

    Find out more on our Breaking Research News page >> http://qoo.ly/9zrtu.

    Dr Jenny Sharpe, Research Communications Manager at Muscular Dystrophy UK

    Jenny Sharpe
    Participant
    Posts: 0
    Joined: 18/11/2015
Viewing 1 post (of 1 total)

You must be logged in to reply to this topic.

Keep in touch